IVA
Strong SellSinkerInventiva S.A. · Healthcare · France · $1.1B · Avg Vol: $4M/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
8
StockRankGet insider-trade alerts
QualityQuality
21
ValueValue
23
MomentumMomentum
34
P/E (TTM)
—
peers 22.9x
ROE
—
peers -34.6%
D/E
—
peers 0.4x
Dividend %
—
trailing yield
ABOUT INVENTIVA S.A.
Read
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.0M | 20.1M | 10.6M | 5.2M | -28.3% | 7.8M | 5.9M | 15.2% |
| EPS | -0.27 | -0.62 | -1.43 | -2.18 | — | -2.19 | — | — |
| Shares | 236.2M | 236.2M | 236.2M | 193.2M | -18.2% | 236.2M | — | — |
| Debt | 39.7M | 43.1M | 62.4M | 68.8M | 20.1% | 265.0M | — | — |
| Equity | 52.3M | -36.8M | -122.5M | -32.8M | — | — | — | — |
| Op CF | -51.6M | -93.8M | -98.7M | -120.5M | — | -120.4M | — | — |
| Inv CF | 10.2M | -8.9M | 10.0M | -153.0M | — | — | — | — |
| Fin CF | 42.8M | 33.4M | 167.3M | 277.2M | — | — | — | — |
Loading 1Y...
PRICE (1Y)-21.3%
SMA 50SMA 200
Close
$3.78
RSI (14)
15.6
52W High
$7.98
From 52W High
0.5%
SCORE BREAKDOWN
Quality
21
ROIC
-186.2%3.4
ROE
—N/A
GP/Assets
2.7%15.0
Op. Margin
-6710.7%2.9
FCF/Assets
-42.1%8.5
Piotroski
559.6
Int. Cover
-9.6x22.2
D/E Ratio
—N/A
Current Ratio
3.16x57.9
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-6.0x25.0
P/FCF
—N/A
P/B
-19.2x25.0
P/S
115.1x6.0
Div Yield
—N/A
Momentum
34
52W High %
47%20.9
RS 6M
-54%13.1
SMA 50/200
0.89x29.5
EPS Rev 4W
+1.5%78.1
EPS Rev 12W
—N/A
EPS Improve
+63%62.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.1B
P/E (Forward)
-4.6x
Gross Margin
99.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IVA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IVA | Inventiva S.A.(you) | $1.1B | 8 | Strong Sell |
| DBVT | DBV Technologies S.A. | $851M | 8 | Strong Sell |
| 0QAV.L | Nanobiotix S.A. | $627M | 5 | Strong Sell |
| VLA.PA | Valneva SE | $614M | 3 | Strong Sell |
| MEDCL.PA | MedinCell S.A. | $1.0B | 21 | Sell |
| CLLS | Cellectis S.A. | $342M | 6 | Strong Sell |
| GNFT.PA | Genfit S.A. | $835M | 36 | Hold |
| IPHA | Innate Pharma S.A. | $248M | 16 | Strong Sell |
| TNG.PA | Transgene SA | $259M | 18 | Strong Sell |
| ALSEN.PA | Sensorion SA | $162M | 3 | Strong Sell |
Peer medians: ROE -34.6% · P/E 22.9x · Gross margin 69.8%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.